{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:10:16Z","timestamp":1778555416185,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP) infections of the central nervous system (CNS) are associated with high mortality rates. These infections are particularly challenging to treat due to both bacterial resistance and the protective blood\u2013brain barrier. This study aims to evaluate treatment outcomes for CRKP-induced CNS infections and provide insights into effective therapeutic strategies for similar cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on patients with CRKP-positive cerebrospinal fluid (CSF) samples admitted to the CSF Neurosurgery Department of the Aviation General Hospital between August 2019 and November 2021. Data collected included patient demographics, medical history, laboratory results, etiological findings, and antibiotic treatments. Nine patients with CRKP-induced CNS infections who were treated with Ceftazidime-avibactam (CAZ-AVI) were included in the analysis. The study assessed clinical features, treatment courses, and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the nine patients, 88.9% (8\/9) achieved both clinical and etiological cure. One patient experienced relapse 20\u202fdays after initial CSF culture negativity, with the family opting for discontinuation of further treatment. Following infection resolution, patients exhibited varying degrees of neurological improvement, including one case of complete recovery from a comatose state (GCS 6 to GCS 15). Treatment-related adverse effects included transient liver dysfunction in one patient and diarrhea in three, which resolved with symptomatic management. CSF drainage tubes were removed in three patients following treatment, while five required shunt surgery due to hydrocephalus. No relapses were reported in treated patients during a follow-up period of 3\u201312\u202fmonths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravenous CAZ-AVI combined with intracerebroventricular or intrathecal polymyxin B or amikacin demonstrated promising efficacy as a treatment regimen for CRKP-induced CNS infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2025.1604045","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:46Z","timestamp":1761106666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ceftazidime-avibactam for the treatment of central nervous system infection caused by carbapenem-resistant Klebsiella pneumoniae after neurosurgery"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenkai","family":"Cong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenwei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-Spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2146\/ajhp170632","article-title":"Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin","volume":"75","author":"Gofman","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.18433\/j3x31r","article-title":"Ceftazidime\/avibactam: who says you can't teach an old drug new tricks?","volume":"19","author":"Barber","year":"2016","journal-title":"J Pharm Pharm Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/IDR.S306222","article-title":"Successful treatment of ventriculitis caused by MDR\/XDR gram-negative Bacillus using ceftazidime\/avibactam: case series and literature review","volume":"14","author":"Zhou","year":"2021","journal-title":"Infect Drug Resist"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1532608","DOI":"10.3389\/fphar.2025.1532608","article-title":"Treatment of pediatric central nervous system infection caused by carbapenem-resistant Klebsiella pneumoniae with ceftazidime\/avibactam, two cases report and literature review","volume":"16","author":"Qing","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.2147\/IDR.S465004","article-title":"Ceftazidime-avibactam for the treatment of central nervous system infection caused by Pan drug-resistant carbapenem-resistant Klebsiella Pneumoniae: a case report","volume":"17","author":"Zhang","year":"2024","journal-title":"Infect Drug Resist"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.12138\/j.issn.1671-9638.20216183","article-title":"China antimicrobial resistance of bacteria from cerebrospinal fluid specimens: surveillance report from China antimicrobial resistance surveillance system in 2014\u20132019","volume":"20","year":"2021","journal-title":"Chin J Infect Control"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1080\/10408398.2015.1077192","article-title":"(2017) antimicrobial resistance: a global emerging threat to public health systems","volume":"57","author":"Ferri","year":"2017","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1080\/02688697.2018.1530729","article-title":"The treatment of nosocomial meningitis and brain abscess by carbapenem-resistant Klebsiella pneumonia","author":"Chen","year":"2023","journal-title":"Br J Neurosurg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.2147\/IDR.S224509","article-title":"Successful treatment of serious meningitis caused by extremely carbapenem-resistant Enterobacter cloacae (MIC\u226516mg\/L) with i.v. meropenem and i.v. amikacin plus intraventricular amikacin","volume":"12","author":"He","year":"2019","journal-title":"Infect Drug Resist"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/1120009X.2017.1338846","article-title":"Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report","volume":"30","author":"Wu","year":"2018","journal-title":"J Chemother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jcrc.2018.07.025","article-title":"Intraventricular CNS treatment with colistin-tigecycline combination: a case series","volume":"47","author":"Tsolaki","year":"2018","journal-title":"J Crit Care"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pharmthera.2017.07.012","article-title":"Polymyxins for CNS infections: pharmacology and neurotoxicity","volume":"181","author":"Velkov","year":"2018","journal-title":"Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.2147\/IDR.S261510","article-title":"A clinical study on the use of intraventricular polymyxin B supplemented by continuous external ventricular drainage in the treatment of drug-resistant gram-negative Bacilli intracranial infection","volume":"13","author":"Chen","year":"2020","journal-title":"Infect Drug Resist"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and Ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref19","volume-title":"Pharmacokinetics of the new \u03b2-lactamase inhibitor NXL104 in an experimental rabbit meningitis model: Restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K pneumoniae\/\/proceedings of the forty-seventh Interscience conference on antimicrobial agents and chemotherapy[G]","author":"Cottagnoud","year":"2007"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"ofaa349","DOI":"10.1093\/ofid\/ofaa349","article-title":"Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime\/avibactam","volume":"7","author":"Yasmin","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jinf.2013.04.003","article-title":"Treatment and outcome of nine cases of KPC-producing Klebsiella pneumoniae meningitis","volume":"67","author":"Tuon","year":"2013","journal-title":"J Infect"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.885","article-title":"Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a KPC-producing Klebsiella pneumoniae","volume":"3","author":"Samuel","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","article-title":"Activity of ceftazidime-avibactam alone and in combination with ertapenem, Fosfomycin, and tigecycline against Carbapenemase-producing Klebsiella pneumoniae","volume":"25","author":"Ojdana","year":"2019","journal-title":"Microb Drug Resist"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or Fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/microorganisms10010154","article-title":"Real-time optimization of pharmacodynamic target attainment at infection site during treatment of post-neurosurgical ventriculitis caused by carbapenem-resistant gram negatives with ceftazidime-avibactam-based regimens: a report of two cases","volume":"10","author":"Gatti","year":"2022","journal-title":"Microorganisms"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/jac\/dkae035","article-title":"The pharmacokinetics\/pharmacodynamics of ceftazidime\/avibactam for central nervous system infections caused by carbapenem-resistant gram-negatives: a prospective study","volume":"79","author":"Xu","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"107356","DOI":"10.1016\/j.ijantimicag.2024.107356","article-title":"Pharmacodynamic target attainment at infection site during treatment of post-neurosurgical ventriculitis caused by carbapenem-resistant klebsiella pneumoniae with ceftazidime-avibactam-based regimens: a case report","volume":"64","author":"Chen","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"106777","DOI":"10.1016\/j.ijantimicag.2023.106777","article-title":"Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"61","author":"Zhao","year":"2023","journal-title":"Int J Antimicrob Agents"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1604045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:49Z","timestamp":1761106669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1604045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":28,"alternative-id":["10.3389\/fneur.2025.1604045"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1604045","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1604045"}}